Remission in ankylosing spondylitis and axial spondyloarthritides: A modern understanding of the problem
https://doi.org/10.14412/1996-7012-2016-1-48-51
Abstract
The paper discusses possible approaches to determining remission in ankylosing spondylitis (AS) and other axial spondyloarthritides (axSpA). At present, there is no single definition of the concept of remission in axSpA and AS, which is due to both the diversity of manifestations of axSpA and a large number of tools to measure disease activity and the nonsimultaneous change in the degree of clinical and laboratory symptoms, signs of acute inflammation, as evidenced by imaging techniques, and signs of progressive structural changes in the locomotor apparatus in the same patient. Clinical, laboratory, magnetic resonance imaging, and radiographic remissions in a patient cannot be in time, which in turn affects the choice of optimal therapy.
The case report demonstrates problems with treatment correction in a patient who has achieved clinical and laboratory remission in the presence of persistent inflammatory signs in the locomotor apparatus, as shown by imaging techniques. Since the guidelines for the follow-up and treatment of patients with nonradiographic axSpA and AS are similar today, the paper considers remission as a general problem for all subtypes of axSpA.
About the Authors
I. Z. Gaydukova
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
A. P. Rebrov
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
A. A. Shuvalova
V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
Russian Federation
112, Bolshaya Kazachya St., Saratov 410012
References
1. Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007 Apr 21;369(9570):1379-90.
2. Гайдукова ИЗ, Ребров АП. Особенности клинических исследований при спондилоартритах (обзор литературы). Доктор.Ру. 2014;92(4):51-5. [Gaidukova IZ, Rebrov AP. Features of clinical studies in the spondyloarthropathies (literature review). Doktor.Ru. 2014;92(4):51-5. (In Russ.)].
3. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005 Apr;52(4):1000-8.
4. Rudwaleit M, van der Heijde D, Landewe R, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011 Jan;70(1):25-31. doi: 10.1136/ard.2010.133645. Epub 2010 Nov 24.
5. Dandorfer SW, Rech J, Manger B, et al. Differences in the patient's and the physician's perspective of disease in psoriatic arthritis. Semin Arthritis Rheum. 2012 Aug;42(1):32-41. doi: 10.1016/j.semarthrit. 2011.12.003. Epub 2012 Mar 16.
6. Poddubnyy D, van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012 Aug;38(3):601-11. doi: 10.1016/j.rdc.2012. 08.005. Epub 2012 Sep 15.
7. Rios Rodriguez V, Poddubnyy D. Old and new treatment targets in axial spondyloarthritis. RMD Open. 2015 Aug 15;1(Suppl 1):e000054. doi: 10.1136/rmdopen-2015-000054. eCollection 2015.
8. Callhoff J, Sieper J, Weiβ A, et al. Efficacy of TNF α blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322. Epub 2014 Apr 9.
9. Sieper J, Poddubnyy D. Inflammation, new bone formation and treatment options in axial spondyloarthritis. Ann Rheum Dis. 2014 Aug;73(8):1439-41. doi: 10.1136/annrheumdis -2014-205464. Epub 2014 May 8.
10. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.
11. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984 Apr;27(4):361-8.
12. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994 Dec;21(12):2286-91.
13. Lukas C, Landewе R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008. 094870. Epub 2008 Jul 14.
14. Machado PM, Landewe RB, van der Heijde DM. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10. J Rheumatol. 2011 Jul;38(7):1502-6. doi: 10.3899/jrheum.110279.
15. Klarenbeek NB, Koevoets R, van der Heijde DM, et al. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. Ann Rheum Dis. 2011 Oct;70(10):1815-21. doi: 10.1136/ard.2010.149260. Epub 2011 Aug 3.
16. Song IH, Hermann KG, Haibel H, et al. Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis-3-Year data of the ESTHER trial. Semin Arthritis Rheum. 2015 Sep 4. pii: S0049-0172(15)00227-9. doi: 10.1016/j.semarthrit.2015.08.005. [Epub ahead of print].
17. Гайдукова ИЗ, Ребров АП, Нам ИФ, Кирсанова НВ. Эторикоксиб в лечении активного сакроилеита у больных аксиальными спондилоартритами, включая анкилозирующий спондилит. Терапевтический архив. 2014;86(12):42-7. [Gaidukova IZ, Rebrov AP, Nam IF, Kirsanova NV. Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthropathies, including ankylosing spondylitis. Terapevticheskii arkhiv. 2014;86(12):42-7. (In Russ.)].
18. Гайдукова ИЗ, Ребров АП, Поддубный ДА. Эффективность и безопасность вводимого внутривенно метилпреднизолона для лечения пациентов с активным анкилозирующим спондилитом: результаты 12-недельного открытого пилотного исследования (МЕТАЛЛ). Терапевтический архив. 2015;87(5):47-52. [Gaidukova IZ, Rebrov AP, Poddubnyi DA. The efficacy and safety of intravenous methylprednisolone for the treatment of patients with active ankylosing spondylitis: results of a 12-week open pilot study (METALL). Terapevticheskii arkhiv. 2015;87(5): 47-52. (In Russ.)].
19. van den Berg R. Spondyloarthritis – Recognition, Imaging, Treatment. Leiden: Giderprint Eschede; 2014. 240 p
Review
For citations:
Gaydukova IZ, Rebrov AP, Shuvalova AA. Remission in ankylosing spondylitis and axial spondyloarthritides: A modern understanding of the problem. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2016;10(1):48-51. (In Russ.) https://doi.org/10.14412/1996-7012-2016-1-48-51
Views:
1744
Email this article 